| 30.71 0.873 (2.92%) | 04-23 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.84 | 1-year : | 38.45 |
| Resists | First : | 31.54 | Second : | 32.92 |
| Pivot price | 31.06  |
|||
| Supports | First : | 29.32 | Second : | 24.39 |
| MAs | MA(5) : | 29.96 |
MA(20) : | 31.43 |
| MA(100) : | 30.78 |
MA(250) : | 29.89 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 10.1 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 32.92 | Low : | 25.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HELX ] has closed above bottom band by 40.7%. Bollinger Bands are 106.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 29.91 - 30.11 | 30.11 - 30.28 |
| Low: | 29.14 - 29.4 | 29.4 - 29.63 |
| Close: | 29.44 - 29.85 | 29.85 - 30.21 |
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Tue, 09 Apr 2024
5 Best Biotech ETFs To Buy - Insider Monkey
Mon, 06 Nov 2023
Franklin Templeton Launches Franklin Focused Growth ETF (FFOG) - Business Wire
Thu, 18 May 2023
Revvity (RVTY) Stock Price, News & Analysis - NYSE - MarketBeat
Fri, 11 Dec 2020
4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis - MarketBeat
Mon, 05 Oct 2020
Best Mutual Funds: Top Manager Runs 3 New ETFs - Investor's Business Daily
Tue, 26 May 2020
3 Genomics ETFs Worth Jumping For - ARK Genomic Revolution ETF (BATS:ARKG), Global X Genomics & Biotechno - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
ETF
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|